Welcome, Guest. Please login or register.
October 04, 2023, 11:51:41 am

Login with username, password and session length

  • Total Posts: 55101
  • Total Topics: 4848
  • Online Today: 106
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 68
Total: 68


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: NASH Is the Second Leading Indication for Liver Transplants  (Read 4457 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
NASH Is the Second Leading Indication for Liver Transplants
« on: December 21, 2020, 12:09:04 pm »
Non-alcoholic steatohepatitis (NASH) is the second most common—and fastest-growing—indication for liver transplants in the United States, according to a study in Clinical Gastroenterology and Hepatology. Moreover, among women without hepatocellular carcinoma (HCC), NASH is already the leading reason for a liver transplant.

Changing trends in obesity and the development of better treatments for viral hepatitis have altered the picture of chronic liver disease in the United States. While vaccines can prevent hepatitis B and new treatments can cure hepatitis C, the prevalence of obesity and type 2 diabetes have shot up, increasing the risk of non-alcoholic fatty liver disease (NAFLD) and NASH, its more severe form.



© 2023 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.